Conducts clinical trials for biotechnology and pharmaceutical companies.
Sep 2026Revenue $2.84B/yrExpenses $2.23B/yr
No trend
Figures by year
Is Medpace Holdings profitable?
Yes. In the 12 months to Sep 2026, revenue was $2.84B and expenses $2.23B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.53B | $2.00B | $535M |
| Dec 2024 | $2.11B | $1.66B | $447M |
| Dec 2023 | $1.89B | $1.55B | $337M |
| Dec 2022 | $1.46B | $1.18B | $279M |
| Dec 2021 | $1.14B | $944M | $199M |
| Dec 2020 | $926M | $759M | $167M |
| Dec 2019 | $861M | $734M | $127M |
| Dec 2018 | $705M | $604M | $101M |
| Dec 2017 | $436M | $371M | $64.9M |
| Dec 2016 | $422M | $369M | $52.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.